IL6 and neoplasm: One such approach involves tocilizumab, a humanized monoclonal antibody (mAb) that blocks both soluble and membrane-bound IL-6 receptors, thereby inhibiting IL-6-driven signaling pathways implicated in tumor progression, particularly in TNBC.